Eurocine Vaccines and Redbiotec have signed a research and collaboration agreement for the development of vaccine candidates against herpes simplex virus type 2. Under the terms of the agreement, Eurocine will have exclusive international rights to develop, manufacture and commercialise the vaccines. On the other hand, the vaccines are being developed using Redbiotec’s technologies. The agreement includes both mRNA and protein-based technologies for the herpesvirus domain (HSV-2). HSV-2 is a sexually transmitted disease that is primarily treated with antivirals. There is currently no effective therapeutic vaccine on the market, hence the importance of the agreement.
VISCHER has supported Redbiotec in this partnership. The team has been led by corporate partner Matthias Staehelin (pictured left) and Christoph Enz (associate, pictured right).